JPH0430926B2 - - Google Patents

Info

Publication number
JPH0430926B2
JPH0430926B2 JP60034581A JP3458185A JPH0430926B2 JP H0430926 B2 JPH0430926 B2 JP H0430926B2 JP 60034581 A JP60034581 A JP 60034581A JP 3458185 A JP3458185 A JP 3458185A JP H0430926 B2 JPH0430926 B2 JP H0430926B2
Authority
JP
Japan
Prior art keywords
nasal administration
lower alkyl
powder composition
alkyl ether
calcitonin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP60034581A
Other languages
English (en)
Japanese (ja)
Other versions
JPS61194034A (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to JP60034581A priority Critical patent/JPS61194034A/ja
Priority to EP86301317A priority patent/EP0193372B1/en
Priority to DE8686301317T priority patent/DE3676515D1/de
Publication of JPS61194034A publication Critical patent/JPS61194034A/ja
Priority to MYPI87000102A priority patent/MY102422A/en
Priority to US07/132,447 priority patent/US4985242A/en
Publication of JPH0430926B2 publication Critical patent/JPH0430926B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP60034581A 1985-02-25 1985-02-25 経鼻投与用粉末状組成物 Granted JPS61194034A (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP60034581A JPS61194034A (ja) 1985-02-25 1985-02-25 経鼻投与用粉末状組成物
EP86301317A EP0193372B1 (en) 1985-02-25 1986-02-24 Intranasally applicable powdery pharmaceutical composition
DE8686301317T DE3676515D1 (de) 1985-02-25 1986-02-24 Intranasal applizierbare pharmazeutische puder.
MYPI87000102A MY102422A (en) 1985-02-25 1987-02-05 Intranasally applicable powdery pharmaceutical composition.
US07/132,447 US4985242A (en) 1985-02-25 1987-12-14 Intranasally applicable powdery pharmaceutical composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP60034581A JPS61194034A (ja) 1985-02-25 1985-02-25 経鼻投与用粉末状組成物

Publications (2)

Publication Number Publication Date
JPS61194034A JPS61194034A (ja) 1986-08-28
JPH0430926B2 true JPH0430926B2 (enExample) 1992-05-25

Family

ID=12418284

Family Applications (1)

Application Number Title Priority Date Filing Date
JP60034581A Granted JPS61194034A (ja) 1985-02-25 1985-02-25 経鼻投与用粉末状組成物

Country Status (5)

Country Link
US (1) US4985242A (enExample)
EP (1) EP0193372B1 (enExample)
JP (1) JPS61194034A (enExample)
DE (1) DE3676515D1 (enExample)
MY (1) MY102422A (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3601923A1 (de) * 1986-01-23 1987-07-30 Behringwerke Ag Nasal applizierbares arzneimittel, verfahren zu seiner herstellung und seine verwendung
MY102411A (en) * 1986-12-23 1992-06-17 Ciba Geigy Ag Nasal solutions
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
KR890006252A (ko) * 1987-10-15 1989-06-12 헤르비그 폰 모르체 분말형 폴리펩타이드의 비강내 투여용 조성물 및 투여방법
NZ228285A (en) * 1988-03-11 1991-08-27 Teikoku Seiyaku Kk Pharmaceutical composition comprising a polypeptide and adapted for intravaginal administration
US5260270A (en) * 1988-03-30 1993-11-09 The Johns Hopkins University Odorant-binding protein from rat
EP0360340A1 (en) * 1988-09-19 1990-03-28 Akzo N.V. Composition for nasal administration containing a peptide
US5514365A (en) * 1988-10-11 1996-05-07 Schiapparelli Salute S.P.A. Pharmaceutical compositions comprising calcitonin for intranasal administration
IL91856A0 (en) * 1988-10-11 1990-06-10 Schiapparelli Salute Spa Pharmaceutical compositions comprising calcitonin for intranasal administration and a spray unit for the administration of the same
JPH02104531A (ja) * 1988-10-14 1990-04-17 Toyo Jozo Co Ltd 経鼻投与用生理活性ペプチド組成物
US5567682A (en) * 1988-12-16 1996-10-22 Advanced Peptides And Biotechnology Sciences Method of treating Alzheimer's disease
JP2704546B2 (ja) * 1989-04-04 1998-01-26 光利 太良 Ａｔｌｌ治療用吸入剤
JP2514249B2 (ja) * 1989-05-23 1996-07-10 帝人株式会社 安定化されたカルシトニン類医薬組成物
US5422340A (en) * 1989-09-01 1995-06-06 Ammann; Arthur J. TGF-βformulation for inducing bone growth
JP2911496B2 (ja) * 1989-09-11 1999-06-23 帝國製薬株式会社 生理活性ポリペプチド含有高吸収性経膣剤
EP0432431B1 (en) * 1989-11-16 1993-06-16 PHIDEA S.p.A. Liquid pharmaceutical composition for nasal administration containing a polypeptide as active ingredient
GB9000459D0 (en) * 1990-01-09 1990-03-07 James Michael H Medicaments for treatment of airborne allergies
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
EP0462305B1 (de) * 1990-06-21 1994-11-02 Huland, Edith, Dr. Dr. Verwendung zytokinhaltiger Aerosole und zytokinhaltige Aerosole selbst
US5780012A (en) * 1990-06-21 1998-07-14 Huland; Edith Method for reducing lung afflictions by inhalation of cytokine solutions
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
IT1242019B (it) * 1990-11-20 1994-02-02 Ripari Gero Ist Farm Biolog Composizioni farmaceutiche acquose a base di calcitonina, da somministrarsi per via nasale.
JP3179538B2 (ja) * 1990-12-11 2001-06-25 ノバルティス アクチエンゲゼルシャフト 安定なヒトカルシトニンの水性溶液
US5093105A (en) * 1991-04-09 1992-03-03 Merck Frosst Canada, Inc. Radiopharmaceutical bacteriostats
US5306482A (en) * 1991-04-09 1994-04-26 Merck Frosst Canada, Inc. Radiopharmaceutical bacteriostats
US5227152A (en) * 1991-04-09 1993-07-13 Merck Frosst Canada, Inc. Radiopharmaceutical bacteriostats
JPH06510754A (ja) * 1991-05-24 1994-12-01 アミリン・ファーマシューティカルズ，インコーポレイテッド 食欲不振および関連症状の治療用のアミリンおよび可能性としてインスリンを含有する組成物
DE4222647A1 (de) * 1991-07-15 1993-01-21 Sandoz Ag Peptid-zubereitungen
AU2348492A (en) * 1991-07-19 1993-02-23 East Carolina University Method of treating asthma
US5571788A (en) * 1991-12-09 1996-11-05 Ciba-Geigy Corporation Stable calcitonin pharmaceutical compositions
US5192743A (en) * 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
ATE222754T1 (de) * 1992-06-12 2002-09-15 Teijin Ltd Ultrafeines pulver zur inhalation und dessen herstellung
US5626871A (en) * 1992-06-12 1997-05-06 Teijin Limited Preparation for intratracheobronchial administration
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
PT708657E (pt) * 1993-06-29 2001-11-30 Ferring Bv Composicoes para administracao nasal de desmopressina
ATE264096T1 (de) 1994-03-07 2004-04-15 Nektar Therapeutics Verfahren und mittel zur verabreichung von insulin über die lunge
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
EP0954326B2 (en) 1996-04-19 2009-07-22 Grifols Inc. A process for viral inactivation of lyophilized blood proteins
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6190699B1 (en) * 1998-05-08 2001-02-20 Nzl Corporation Method of incorporating proteins or peptides into a matrix and administration thereof through mucosa
DE19826628C1 (de) * 1998-06-17 2000-07-20 Werner Kern Intranasale Verwendung von Insulin bei Hirnleistungsstörungen
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
US6540982B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US20030138460A1 (en) * 2000-02-08 2003-07-24 Allergan, Inc Methods of treating animals with botulinum toxin pharmaceutical compositions
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
CA2494241C (en) * 2000-02-08 2011-06-14 Allergan, Inc. Botulinum toxin pharmaceutical compositions
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
JP4711520B2 (ja) * 2000-03-21 2011-06-29 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
US20020146409A1 (en) * 2001-01-30 2002-10-10 Herring Steven W. Methods for stabilizing lyophilized blood proteins
CA2439097C (en) * 2001-03-26 2010-10-12 Novartis Ag Pharmaceutical compositions
WO2003072016A2 (en) * 2001-11-19 2003-09-04 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
US20040005999A1 (en) * 2002-03-07 2004-01-08 Andreasen Kasper Huus Polyamino acid-based particle insulin preparation
US7812120B2 (en) 2003-03-21 2010-10-12 Par Pharmaceutical, Inc. Nasal calcitonin formulations containing chlorobutanol
US20050058673A1 (en) 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
WO2005094785A2 (en) * 2003-09-17 2005-10-13 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
US9028852B2 (en) 2004-09-07 2015-05-12 3M Innovative Properties Company Cationic antiseptic compositions and methods of use
US20060051384A1 (en) * 2004-09-07 2006-03-09 3M Innovative Properties Company Antiseptic compositions and methods of use
US8198326B2 (en) * 2004-09-07 2012-06-12 3M Innovative Properties Company Phenolic antiseptic compositions and methods of use
GB0422582D0 (en) * 2004-10-11 2004-11-10 Nasaleze Patents Ltd Pharmaceutical compositions
EP1824450B1 (en) * 2004-10-11 2012-11-14 Nasaleze Patents Limited Compositions for intranasal administration
US7396936B1 (en) 2004-11-09 2008-07-08 Kemia, Inc. Modulators of calcitonin and amylin receptor activity
CA2599667C (en) * 2005-03-10 2014-12-16 3M Innovative Properties Company Antimicrobial compositions comprising esters of hydroxy carboxylic acids
CN101137359B (zh) * 2005-03-10 2011-01-12 3M创新有限公司 治疗耳感染的方法
TW200716200A (en) * 2005-03-10 2007-05-01 3M Innovative Properties Co Methods of reducing microbial contamination
US7580130B2 (en) * 2005-03-23 2009-08-25 Datacolor Holding Ag Method for designing a colorimeter having integral illuminant-weighted CIE color-matching filters
JP2007084508A (ja) * 2005-09-26 2007-04-05 Shiseido Co Ltd 新規血管内皮増殖因子発現阻害剤
CN101489379B (zh) 2006-10-27 2014-06-04 3M创新有限公司 抗微生物组合物
US9789071B2 (en) 2012-06-27 2017-10-17 G2B Pharma, Inc. Intranasal formulation of epinephrine for the treatment of anaphylaxis
MX2016002705A (es) * 2013-09-03 2016-09-06 G2B Pharma Inc Formulacion intranasal para el tratamiento por reanimacion cardiopulmonar (rcp), mantenimiento cardiaco vital (cls), de anafilaxia y/o reacciones anafilactoides.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3169095A (en) * 1962-10-30 1965-02-09 Rexall Drug Chemical Self-propelling powder-dispensing compositions
CA986441A (en) * 1971-10-22 1976-03-30 Aslam Khwaja Enzyme treatment
JPS6034925B2 (ja) * 1979-07-31 1985-08-12 帝人株式会社 持続性鼻腔用製剤およびその製造法
JPS58189118A (ja) * 1982-04-30 1983-11-04 Takeda Chem Ind Ltd 経鼻投与製剤
GB2127689B (en) * 1982-10-05 1986-07-09 Sandoz Ltd Calcitonin inhalation compositions
JPS5989619A (ja) * 1982-10-05 1984-05-23 サンド・アクチエンゲゼルシヤフト カルシトニン組成物およびその用途
IL70489A0 (en) * 1982-12-29 1984-03-30 Armour Pharma Pharmaceutical compositions containing calcitonin
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物

Also Published As

Publication number Publication date
DE3676515D1 (de) 1991-02-07
MY102422A (en) 1992-06-30
JPS61194034A (ja) 1986-08-28
EP0193372A2 (en) 1986-09-03
EP0193372A3 (en) 1987-07-01
US4985242A (en) 1991-01-15
EP0193372B1 (en) 1990-12-27

Similar Documents

Publication Publication Date Title
JPH0430926B2 (enExample)
CA2179207C (en) Parathyroid hormone formulation
EP0122036B2 (en) Powdery pharmaceutical composition for nasal administration
US4690952A (en) Pharmaceutical compositions for nasal administration comprising calcitonin and an absorption-promoting substance
US7235253B2 (en) Powder containing physiologically active peptide
JPH09208485A (ja) ペプチド・蛋白質性薬物の水難溶性組成物
CA2375914A1 (en) Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
JPH05963A (ja) ポリペプチド類組成物
JPH10501519A (ja) インシュリンを肺に送給できる方法および組成物
JPH05508616A (ja) 治療用エアロゾル剤
JP2002363097A (ja) 安定化された凍結乾燥型医薬組成物
JPS6242888B2 (enExample)
JPS632932A (ja) 経鼻投与用粉末状組成物
GB2193891A (en) Nasal pharmaceutical compositions containing octreotide
EP0938902A1 (en) Human growth hormone-containing aqueous pharamceutical composition
JP2505430B2 (ja) 塩基性アミノ酸を含有する経鼻投与用粉末状組成物
JPH02111A (ja) 経鼻投与用生理活性ペプチド製剤
JPH0338255B2 (enExample)
JPH0441421A (ja) 肺吸収組成物
JPH0480008B2 (enExample)
JPH0688898B2 (ja) アスコルビン酸類を含有する経鼻投与用粉末状組成物
JPH09309843A (ja) ヒアルロン酸含有経肺投与用製剤
JPH0578258A (ja) 安定なカルシトニン医薬組成物及びその製造法
JP3181391B2 (ja) 経鼻投与用製剤
CN114432432A (zh) 一种吸入制剂

Legal Events

Date Code Title Description
EXPY Cancellation because of completion of term